Understanding the Landscape of Immune Checkpoint Inhibitor Therapy in Early-Stage NSCLC: A Shared Decision-Making Resource for Clinicians and Patients

Download this patient-friendly PDF summarizing key points on using immune checkpoint inhibitors for early-stage NSCLC, from ongoing clinical trials to monitoring for and managing immune-related adverse events.
Elizabeth Krueger, NP
Format: Adobe Acrobat (.pdf)
File Size: 527 KB
Released: September 22, 2021

Information on this Educational Activity

Faculty

Elizabeth Krueger, NP

Nurse Practitioner
Thoracic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Elizabeth Krueger, NP, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021

Downloadable slideset on the use of neoadjuvant immunotherapy in resectable early-stage lung cancer, from Clinical Care Options (CCO)

Released: December 1, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on EGFR Exon 20–Altered NSCLC.

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Released: December 1, 2021

PDF transcript of a podcast where lung cancer experts answer clinical questions on evolving immunotherapy strategies for NSCLC, from Clinical Care Options (CCO)

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: December 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue